The International Collaboration on Cosmetics Safety ushers in a new phase as its 2026 Board officers take their roles, strengthening its worldwide dedication to promoting animal-free innovations in cosmetics safety science amid swift regulatory and scientific shifts.
The International Collaboration on Cosmetics Safety (ICCS) has confirmed its Board officers for 2026, following elections held during the organization’s December 2025 Board meeting. The announcement marks a significant milestone for the relatively young global initiative, which continues to position itself at the forefront of efforts to replace animal testing in cosmetics safety assessment with scientifically robust, human-relevant alternatives. The newly elected leadership reflects both continuity and growing maturity within ICCS, as the organization builds on a year of substantial progress and looks ahead to expanding its impact across regulatory, scientific, and industry communities worldwide.
ICCS operates at the nexus of science, policy, and cooperative action, uniting varied stakeholders who pursue the shared goal of advancing the worldwide shift toward animal-free safety science for cosmetics and their ingredients. The confirmation of the 2026 Board officers highlights the organization’s commitment to preserving strategic direction as it navigates an increasingly intricate global landscape, where expectations surrounding ethical research, scientific precision, and regulatory coherence continue to advance.
Ongoing leadership stability and worldwide representation
The 2026 Board leadership brings together senior figures from across the cosmetics, consumer products, and regulatory advocacy sectors, reflecting the multi-stakeholder nature that has defined ICCS since its inception. Stéphane Dhalluin, Ph.D., DABT, Global Head of Human & Environmental Safety Evaluation at L’Oréal, has been re-elected as Chair of the Board of Directors. His reappointment signals confidence in a leadership approach that has emphasized scientific credibility, global cooperation, and constructive engagement with regulators.
Serving with him as Vice Chair is Darren Praznik, President and Chief Executive Officer of Cosmetics Alliance Canada, whose extensive record in industry advocacy and regulatory collaboration delivers a solid regional perspective shaped by policy expertise. The position of Secretary will be taken on by Heike Scheffler, Ph.D., Safety Advocacy and Regulatory Toxicology Director for Global Product Stewardship in Beauty and Oral Care at Procter & Gamble, contributing wide-ranging knowledge in regulatory toxicology and global product safety frameworks. Michael Southall, Ph.D., Senior Director and Head of Global Toxicology and Clinical Safety within Medical Clinical & Safety Sciences at Kenvue, has been named Treasurer, providing deep leadership experience in toxicology and organizational governance.
Together, the officers form a Board leadership team that spans multinational corporations, industry associations, and regulatory science, reinforcing ICCS’ position as a neutral platform for collaboration rather than advocacy for any single sector. This balance is central to the organization’s credibility, particularly as it seeks to influence regulatory thinking and encourage convergence around animal-free safety methodologies.
Advancing animal-free scientific innovation through united collaboration
At the core of ICCS’ mission lies the conviction that animal-free safety assessment methods, when rigorously designed and validated, are not only ethically favorable but also scientifically stronger. Since its establishment in early 2023, ICCS has sought to show that non-animal approaches can deliver dependable, relevant insights to safeguard both human well-being and the environment. The confirmation of the 2026 Board officers arrives at a time when this message is gaining momentum, bolstered by concrete achievements and increasing involvement from regulators worldwide.
Throughout 2025, ICCS rolled out multiple initiatives that strengthened its scientific foundation while extending its overall impact. Among these, it released a Best Practice Guidance document designed to bring greater clarity and consistency to the application of animal‑free safety assessment approaches. This resource aimed to bridge the divide between scientific advances and regulatory expectations, offering a practical tool that stakeholders could rely on when producing or evaluating non‑animal data.
In parallel, ICCS also played a key role in shaping innovative methodologies that align with next generation risk assessment (NGRA), an evolving framework that integrates advanced in vitro, in silico, and exposure-led approaches. These techniques are increasingly viewed as essential to modern toxicology, offering more human-relevant insights while reducing reliance on animal testing. ICCS’ efforts in this field highlight its commitment to ethical advancement and scientific excellence.
ICCS has also placed strong importance on open dialogue, and throughout 2025 the organization engaged widely with regulators, scientists, and policymakers in various regions, helping shape conversations about how animal-free data can be interpreted and integrated into current regulatory systems, a series of exchanges that has significantly advanced mutual understanding and confidence, especially in regions where the approval of non-animal approaches is still evolving.
A pivotal milestone reshaping the oversight of cosmetics safety
The appointment of the 2026 Board officers takes place against a backdrop of significant change in global cosmetics regulation. Many markets are reassessing long-standing testing requirements, responding to public expectations, scientific advances, and international policy trends. In this context, organizations like ICCS play a critical role in helping align innovation with regulation, ensuring that progress is both credible and sustainable.
ICCS leadership has long underscored that moving toward animal‑free safety science cannot progress through isolated initiatives; rather, it demands synchronized engagement from industry, academia, regulatory bodies, and civil society. The Board’s makeup embodies this principle by uniting figures who grasp the technical, regulatory, and organizational aspects required to drive meaningful transformation.
ICCS leadership statements after the elections conveyed a blend of confidence and pragmatism. They noted the progress achieved in recent years while recognizing that substantial challenges persist. Securing broad regulatory endorsement for animal-free methodologies will demand sustained research investment, open data dissemination, and continuous collaboration with authorities to respond to valid concerns about reliability, real-world relevance, and safeguarding public health.
The re-elected Chair highlighted how crucial it is to harness ICCS’ global, multi-stakeholder framework to narrow the divide between innovation and regulation, ensuring that progress in animal-free science moves beyond laboratories and becomes reliable, consistently applicable tools that regulators can confidently use.
Reinforcing the groundwork for lasting influence
As ICCS looks ahead to 2026 and beyond, the organization is focused on consolidating its achievements while expanding its reach. The newly confirmed Board leadership is expected to play a central role in shaping priorities that balance scientific ambition with practical implementation. This includes identifying areas where additional guidance or consensus-building is needed, supporting the validation and communication of new methodologies, and fostering international alignment to reduce fragmentation in regulatory requirements.
Education remains a core element of ICCS’ strategy, as the organization works to provide accessible, science‑based resources and forums for discussion that illuminate the foundations of animal‑free safety science and enable well‑informed decision‑making. This mission becomes particularly crucial in a field where misconceptions or uneven expertise may slow progress, even when the underlying science is strong.
The organization’s structure, encompassing leading cosmetics and ingredient producers alongside trade and research groups as well as animal protection organizations, places it in a distinctive position to tackle these challenges. This broad range of viewpoints helps keep discussions balanced, well‑rooted, and oriented toward common objectives rather than limited agendas.
Headquartered in New York, ICCS continues to operate as a global initiative, reflecting the inherently international nature of cosmetics development and regulation. Products and ingredients often move across borders, making harmonization and mutual recognition of safety approaches increasingly important. Through its collaborative model, ICCS seeks to contribute to this harmonization, reducing duplication and fostering trust in animal-free science worldwide.
By confirming its 2026 Board officers, ICCS underscores both consistency and a clear drive toward progress, with a leadership group that extends the momentum of a year defined by tangible accomplishments while offering the insight and expertise required to steer the coming stage of transformation; as scientific innovation quickens and regulatory expectations shift, the organization’s function as a unifying force and driver of animal-free cosmetics safety science is poised to gain even greater significance.
Ultimately, the importance of the 2026 Board elections rests not only on who is selected, but also on what their leadership conveys: a continued dedication to cooperation, scientific rigor, and the ethical progress of alternatives to animal testing. For ICCS and its stakeholders, the years ahead present a chance to turn ambition into enduring results, guiding the evolution of cosmetics safety in a manner that brings ethics, scientific excellence, and global public confidence into alignment.
